TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Tumor-infiltrating lymphocytes as a feasible adjuvant immunotherapy for osteosarcoma with a poor response to neoadjuvant chemotherapy

(2020) Jing Shi et al.   Immunotherapy

PD-1/PD-L1 Inhibitors in Cervical Cancer

(2019) Yuncong Liu et al.   Frontiers in Pharmacology

Identification and transcriptome analysis of erythroblastic island macrophages

(2019) Wei Li et al.   BLOOD

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Hyun Cheol Chung et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response

(2019) Florence Baettig et al.   Journal for ImmunoTherapy of Cancer

Cervical cancer – State of the science: From angiogenesis blockade to checkpoint inhibition

(2018) Lindsey E. Minion et al.   GYNECOLOGIC ONCOLOGY

Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial

(2018) Sudeep Gupta et al.   JOURNAL OF CLINICAL ONCOLOGY

Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients

(2018) Mélanie Saint-Jean et al.   Journal of Immunology Research

A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers

(2018) Sanja Stevanovic et al.   CLINICAL CANCER RESEARCH

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

(2017) Jean-Sebastien Frenel et al.   JOURNAL OF CLINICAL ONCOLOGY

Update on immune checkpoint inhibitors in gynecological cancers

(2017) Valerie Heong et al.   Journal of Gynecologic Oncology

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

(2017) Krishnansu S Tewari et al.   LANCET

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma

(2017) Wei Li et al.   Journal of Immunology Research

PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR

(2016) Elise A. Chong et al.   BLOOD

Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy

(2016) C. S. Hinrichs   CLINICAL CANCER RESEARCH

Dual Faces of IFN  in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity

(2016) M. Mandai et al.   CLINICAL CANCER RESEARCH

RECIST 1.1—Update and clarification: From the RECIST committee

(2016) Lawrence H. Schwartz et al.   EUROPEAN JOURNAL OF CANCER

Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells

(2015) Sanja Stevanović et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer

(2012) X. Yao et al.   BLOOD

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Systems modelling approaches to the design of safe healthcare delivery: ease of use and usefulness perceived by healthcare workers

(2010) Gyuchan Thomas Jun et al.   ERGONOMICS

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Cervical cancer incidence among 6 Asian ethnic groups in the United States, 1996 through 2004

(2009) Sophia S. Wang et al.   CANCER

Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity

(2009) Jill Barnholtz-Sloan et al.   CANCER CAUSES & CONTROL

Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression

(2009) Ethan M. Shevach   IMMUNITY

Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

(2009) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of therapeutic HPV vaccines

(2009) Cornelia L Trimble et al.   LANCET ONCOLOGY

Regulatory T cells exert checks and balances on self tolerance and autoimmunity

(2009) Kajsa Wing et al.   NATURE IMMUNOLOGY